12_9_14_CIMA_La interrelación clínica-investigación-empresa no solo da origen a una traslacionalidad hacia el paciente, sino también hacia la sociedad
The clinical interrelationship -research-business "not only gives rise to a translationality towards the patient, but also towards society".
The Full Professor and director of area of Gene Therapy and Hepatology of CIMA delivers the inaugural lecture at the opening of the 2012-2013 academic year.
"The University offers the most suitable environment for the stage of finding of new medicines, as it is a place of meeting of very varied disciplines and diverse fields of knowledge. On the other hand, the pharmaceutical industry is realizing that its strength lies in the development of drugs and not in the finding phase. This is leading to a process of rapprochement between industry and academia, seeking synergistic cooperation". This was stated by Professor Jesús Prieto, Full Professor of Internal Medicine at the University of Navarra, who gave the inaugural lecture at the opening of the 2012-2013 academic year. degree scroll The lecture was entitled "The translational medical research in the university setting".
For Professor Prieto, the university institution "cannot be a passive channel of knowledge, but through the research it must enrich the conceptual flow and improve the clinical internship ".
Thus, he opted for the "translational medicalresearch ", which starts from the patient and returns to him with therapeutic solutions: "Despite the remarkable progress of modern biomedicine, there are still many diseases that lack effective treatment and continue to be source of considerable suffering in the population. Faced with these situations, the physician is compelled to take the problems posed by the patient to laboratory to try to better understand, through the experimental method, the mechanisms of the disease and thus be able to design new and more effective treatments".
The Full Professor Jesús Prieto indicated that the clinical-research-business interrelationship "not only gives rise to translationality towards the patient, but also towards society, since together with better medical treatments it gives rise to new and more profitable companies".
Along these lines, he insisted that, given the current economic situation, "the promotion of university-investor consortia -business and the promotion of the biopharmaceutical and biotechnological industry constitute elements for a strategy of development that should be a priority for the state and autonomous administrations of our country".